Precision clinical medicine · 2025
Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Changshu, Liang Shufan, Wang Xue, Lui Su, Wang Chengdi
Аннотация
OBJECTIVES: To investigate the risk factors in patients with drug-resistant tuberculosis (DR-TB) and clinical characteristics related to unfavorable anti-TB treatment outcomes.
METHODS: A total of 961 pulmonary tuberculosis (TB) patients were included at West China Hospital of Sichuan University from January 2008 to November 2023. We analyzed the differences of clinical characteristics between DR-TB and drug-sensitive tuberculosis (DS-TB), and then compared these features in DR-TB patients with different outcomes. Multivariable logistic regression models were employed to quantify risk factors associated with DR-TB and adverse treatment outcomes.
RESULTS: Among 961 pulmonary TB patients, a history of anti-TB treatment [odds ratio (OR), 3.289; 95% confidence interval (CI), 2.359-4.604] and CT-scan cavities (OR, 1.512; 95% CI, 1.052-2.168) increased DR-TB risk. A total of 214 DR-TB patients were followed for a median of 24.5 months. Among them, 116/214 (54.2%) patients achieved favorable outcomes. Prior anti-TB treatment (OR, 1.927; 95% CI, 1.033-3.640), multidrug-resistant tuberculosis (MDR-TB) (OR, 2.558; 95% CI, 1.272-5.252), positive sputum bacteriology (OR, 2.116; 95% CI, 1.100-4.134), and pleural effusion (OR, 2.097; 95% CI, 1.093-4.082) were associated with unfavorable outcomes, while isoniazid-resistant TB patients showed better outcomes (OR, 0.401; 95% CI, 0.181-0.853). The clinical model for unfavorable outcome prediction of DR-TB achieved an area under the curve (AUC) of 0.754 (95% CI, 0.690-0.818).
CONCLUSIONS: Treatment history of anti-TB not only increases the risk of the emergence of DR-TB, but also potentially leads to treatment failure during re-treatment in DR-TB patients. Drug resistance subtypes, radiological characteristics, and the results of sputum smear or culture may affect the treatment outcome of DR-TB.
METHODS: A total of 961 pulmonary tuberculosis (TB) patients were included at West China Hospital of Sichuan University from January 2008 to November 2023. We analyzed the differences of clinical characteristics between DR-TB and drug-sensitive tuberculosis (DS-TB), and then compared these features in DR-TB patients with different outcomes. Multivariable logistic regression models were employed to quantify risk factors associated with DR-TB and adverse treatment outcomes.
RESULTS: Among 961 pulmonary TB patients, a history of anti-TB treatment [odds ratio (OR), 3.289; 95% confidence interval (CI), 2.359-4.604] and CT-scan cavities (OR, 1.512; 95% CI, 1.052-2.168) increased DR-TB risk. A total of 214 DR-TB patients were followed for a median of 24.5 months. Among them, 116/214 (54.2%) patients achieved favorable outcomes. Prior anti-TB treatment (OR, 1.927; 95% CI, 1.033-3.640), multidrug-resistant tuberculosis (MDR-TB) (OR, 2.558; 95% CI, 1.272-5.252), positive sputum bacteriology (OR, 2.116; 95% CI, 1.100-4.134), and pleural effusion (OR, 2.097; 95% CI, 1.093-4.082) were associated with unfavorable outcomes, while isoniazid-resistant TB patients showed better outcomes (OR, 0.401; 95% CI, 0.181-0.853). The clinical model for unfavorable outcome prediction of DR-TB achieved an area under the curve (AUC) of 0.754 (95% CI, 0.690-0.818).
CONCLUSIONS: Treatment history of anti-TB not only increases the risk of the emergence of DR-TB, but also potentially leads to treatment failure during re-treatment in DR-TB patients. Drug resistance subtypes, radiological characteristics, and the results of sputum smear or culture may affect the treatment outcome of DR-TB.